Characterization of germline antibody libraries from human umbilical cord blood and selection of monoclonal antibodies to viral envelope glycoproteins: Implications for mechanisms of immune evasion and design of vaccine immunogens.
Identifieur interne : 001420 ( PubMed/Curation ); précédent : 001419; suivant : 001421Characterization of germline antibody libraries from human umbilical cord blood and selection of monoclonal antibodies to viral envelope glycoproteins: Implications for mechanisms of immune evasion and design of vaccine immunogens.
Auteurs : Weizao Chen [États-Unis] ; Emily D. Streaker ; Daniel E. Russ ; Yang Feng ; Ponraj Prabakaran ; Dimiter S. DimitrovSource :
- Biochemical and biophysical research communications [ 1090-2104 ] ; 2012.
Descripteurs français
- KwdFr :
- Anticorps monoclonaux (immunologie), Anticorps monoclonaux (isolement et purification), Anticorps neutralisants (génétique), Anticorps neutralisants (immunologie), Banque de peptides, Données de séquences moléculaires, Glycoprotéines (immunologie), Humains, Immunité acquise, Protéines de l'enveloppe virale (immunologie), Sang foetal (immunologie), Structure tertiaire des protéines, Séquence d'acides aminés, VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (immunologie), Virus Hendra (immunologie), Virus du SRAS (immunologie).
- MESH :
- génétique : Anticorps neutralisants.
- immunologie : Anticorps monoclonaux, Anticorps neutralisants, Glycoprotéines, Protéines de l'enveloppe virale, Sang foetal, VIH-1 (Virus de l'Immunodéficience Humaine de type 1), Virus Hendra, Virus du SRAS.
- isolement et purification : Anticorps monoclonaux.
- Banque de peptides, Données de séquences moléculaires, Humains, Immunité acquise, Structure tertiaire des protéines, Séquence d'acides aminés.
English descriptors
- KwdEn :
- Adaptive Immunity, Amino Acid Sequence, Antibodies, Monoclonal (immunology), Antibodies, Monoclonal (isolation & purification), Antibodies, Neutralizing (genetics), Antibodies, Neutralizing (immunology), Fetal Blood (immunology), Glycoproteins (immunology), HIV-1 (immunology), Hendra Virus (immunology), Humans, Molecular Sequence Data, Peptide Library, Protein Structure, Tertiary, SARS Virus (immunology), Viral Envelope Proteins (immunology).
- MESH :
- chemical , genetics : Antibodies, Neutralizing.
- chemical , immunology : Antibodies, Monoclonal, Antibodies, Neutralizing, Glycoproteins, Viral Envelope Proteins.
- chemical , isolation & purification : Antibodies, Monoclonal.
- immunology : Fetal Blood, HIV-1, Hendra Virus, SARS Virus.
- Adaptive Immunity, Amino Acid Sequence, Humans, Molecular Sequence Data, Peptide Library, Protein Structure, Tertiary.
Abstract
We have previously observed that all known HIV-1 broadly neutralizing antibodies (bnAbs) are highly divergent from germline antibodies in contrast to bnAbs against Hendra virus, Nipah virus and SARS coronavirus (SARS CoV). We have hypothesized that because the germline antibodies are so different from the mature HIV-1-specific bnAbs they may not bind the epitopes of the mature antibodies and provided the first evidence to support this hypothesis by using individual putative germline-like predecessor antibodies. To further validate the hypothesis and understand initial immune responses to different viruses, two phage-displayed human cord blood-derived IgM libraries were constructed which contained mostly germline antibodies or antibodies with very low level of somatic hypermutations. They were panned against different HIV-1 envelope glycoproteins (Envs), SARS CoV protein receptor-binding domain (RBD), and soluble Hendra virus G protein (sG). Despite a high sequence and combinatorial diversity observed in the cord blood-derived IgM antibody repertoire, no enrichment for binders of Envs was observed in contrast to considerable specific enrichments produced with panning against RBD and sG; one of the selected monoclonal antibodies (against the RBD) was of high (nM) affinity with only few somatic mutations. These results further support and expand our initial hypothesis for fundamental differences in immune responses leading to elicitation of bnAbs against HIV-1 compared to SARS CoV and Hendra virus. HIV-1 uses a strategy to minimize or eliminate strong binding of germline antibodies to its Env; in contrast, SARS CoV and Hendra virus, and perhaps other viruses causing acute infections, can bind germline antibody or minimally somatically mutated antibodies with relatively high affinity which could be one of the reasons for the success of sG and RBD as vaccine immunogens.
DOI: 10.1016/j.bbrc.2011.12.089
PubMed: 22226962
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001420
Links to Exploration step
pubmed:22226962Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Characterization of germline antibody libraries from human umbilical cord blood and selection of monoclonal antibodies to viral envelope glycoproteins: Implications for mechanisms of immune evasion and design of vaccine immunogens.</title>
<author><name sortKey="Chen, Weizao" sort="Chen, Weizao" uniqKey="Chen W" first="Weizao" last="Chen">Weizao Chen</name>
<affiliation wicri:level="1"><nlm:affiliation>Protein Interactions Group, Center for Cancer Research Nanobiology Program, National Cancer Institute-Frederick, National Institutes of Health, Frederick, MD 21702, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Protein Interactions Group, Center for Cancer Research Nanobiology Program, National Cancer Institute-Frederick, National Institutes of Health, Frederick, MD 21702</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Streaker, Emily D" sort="Streaker, Emily D" uniqKey="Streaker E" first="Emily D" last="Streaker">Emily D. Streaker</name>
</author>
<author><name sortKey="Russ, Daniel E" sort="Russ, Daniel E" uniqKey="Russ D" first="Daniel E" last="Russ">Daniel E. Russ</name>
</author>
<author><name sortKey="Feng, Yang" sort="Feng, Yang" uniqKey="Feng Y" first="Yang" last="Feng">Yang Feng</name>
</author>
<author><name sortKey="Prabakaran, Ponraj" sort="Prabakaran, Ponraj" uniqKey="Prabakaran P" first="Ponraj" last="Prabakaran">Ponraj Prabakaran</name>
</author>
<author><name sortKey="Dimitrov, Dimiter S" sort="Dimitrov, Dimiter S" uniqKey="Dimitrov D" first="Dimiter S" last="Dimitrov">Dimiter S. Dimitrov</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2012">2012</date>
<idno type="RBID">pubmed:22226962</idno>
<idno type="pmid">22226962</idno>
<idno type="doi">10.1016/j.bbrc.2011.12.089</idno>
<idno type="wicri:Area/PubMed/Corpus">001420</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001420</idno>
<idno type="wicri:Area/PubMed/Curation">001420</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001420</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Characterization of germline antibody libraries from human umbilical cord blood and selection of monoclonal antibodies to viral envelope glycoproteins: Implications for mechanisms of immune evasion and design of vaccine immunogens.</title>
<author><name sortKey="Chen, Weizao" sort="Chen, Weizao" uniqKey="Chen W" first="Weizao" last="Chen">Weizao Chen</name>
<affiliation wicri:level="1"><nlm:affiliation>Protein Interactions Group, Center for Cancer Research Nanobiology Program, National Cancer Institute-Frederick, National Institutes of Health, Frederick, MD 21702, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Protein Interactions Group, Center for Cancer Research Nanobiology Program, National Cancer Institute-Frederick, National Institutes of Health, Frederick, MD 21702</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Streaker, Emily D" sort="Streaker, Emily D" uniqKey="Streaker E" first="Emily D" last="Streaker">Emily D. Streaker</name>
</author>
<author><name sortKey="Russ, Daniel E" sort="Russ, Daniel E" uniqKey="Russ D" first="Daniel E" last="Russ">Daniel E. Russ</name>
</author>
<author><name sortKey="Feng, Yang" sort="Feng, Yang" uniqKey="Feng Y" first="Yang" last="Feng">Yang Feng</name>
</author>
<author><name sortKey="Prabakaran, Ponraj" sort="Prabakaran, Ponraj" uniqKey="Prabakaran P" first="Ponraj" last="Prabakaran">Ponraj Prabakaran</name>
</author>
<author><name sortKey="Dimitrov, Dimiter S" sort="Dimitrov, Dimiter S" uniqKey="Dimitrov D" first="Dimiter S" last="Dimitrov">Dimiter S. Dimitrov</name>
</author>
</analytic>
<series><title level="j">Biochemical and biophysical research communications</title>
<idno type="eISSN">1090-2104</idno>
<imprint><date when="2012" type="published">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adaptive Immunity</term>
<term>Amino Acid Sequence</term>
<term>Antibodies, Monoclonal (immunology)</term>
<term>Antibodies, Monoclonal (isolation & purification)</term>
<term>Antibodies, Neutralizing (genetics)</term>
<term>Antibodies, Neutralizing (immunology)</term>
<term>Fetal Blood (immunology)</term>
<term>Glycoproteins (immunology)</term>
<term>HIV-1 (immunology)</term>
<term>Hendra Virus (immunology)</term>
<term>Humans</term>
<term>Molecular Sequence Data</term>
<term>Peptide Library</term>
<term>Protein Structure, Tertiary</term>
<term>SARS Virus (immunology)</term>
<term>Viral Envelope Proteins (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Anticorps monoclonaux (immunologie)</term>
<term>Anticorps monoclonaux (isolement et purification)</term>
<term>Anticorps neutralisants (génétique)</term>
<term>Anticorps neutralisants (immunologie)</term>
<term>Banque de peptides</term>
<term>Données de séquences moléculaires</term>
<term>Glycoprotéines (immunologie)</term>
<term>Humains</term>
<term>Immunité acquise</term>
<term>Protéines de l'enveloppe virale (immunologie)</term>
<term>Sang foetal (immunologie)</term>
<term>Structure tertiaire des protéines</term>
<term>Séquence d'acides aminés</term>
<term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (immunologie)</term>
<term>Virus Hendra (immunologie)</term>
<term>Virus du SRAS (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Antibodies, Neutralizing</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Monoclonal</term>
<term>Antibodies, Neutralizing</term>
<term>Glycoproteins</term>
<term>Viral Envelope Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="isolation & purification" xml:lang="en"><term>Antibodies, Monoclonal</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Anticorps neutralisants</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps monoclonaux</term>
<term>Anticorps neutralisants</term>
<term>Glycoprotéines</term>
<term>Protéines de l'enveloppe virale</term>
<term>Sang foetal</term>
<term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term>
<term>Virus Hendra</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Fetal Blood</term>
<term>HIV-1</term>
<term>Hendra Virus</term>
<term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Anticorps monoclonaux</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adaptive Immunity</term>
<term>Amino Acid Sequence</term>
<term>Humans</term>
<term>Molecular Sequence Data</term>
<term>Peptide Library</term>
<term>Protein Structure, Tertiary</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Banque de peptides</term>
<term>Données de séquences moléculaires</term>
<term>Humains</term>
<term>Immunité acquise</term>
<term>Structure tertiaire des protéines</term>
<term>Séquence d'acides aminés</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We have previously observed that all known HIV-1 broadly neutralizing antibodies (bnAbs) are highly divergent from germline antibodies in contrast to bnAbs against Hendra virus, Nipah virus and SARS coronavirus (SARS CoV). We have hypothesized that because the germline antibodies are so different from the mature HIV-1-specific bnAbs they may not bind the epitopes of the mature antibodies and provided the first evidence to support this hypothesis by using individual putative germline-like predecessor antibodies. To further validate the hypothesis and understand initial immune responses to different viruses, two phage-displayed human cord blood-derived IgM libraries were constructed which contained mostly germline antibodies or antibodies with very low level of somatic hypermutations. They were panned against different HIV-1 envelope glycoproteins (Envs), SARS CoV protein receptor-binding domain (RBD), and soluble Hendra virus G protein (sG). Despite a high sequence and combinatorial diversity observed in the cord blood-derived IgM antibody repertoire, no enrichment for binders of Envs was observed in contrast to considerable specific enrichments produced with panning against RBD and sG; one of the selected monoclonal antibodies (against the RBD) was of high (nM) affinity with only few somatic mutations. These results further support and expand our initial hypothesis for fundamental differences in immune responses leading to elicitation of bnAbs against HIV-1 compared to SARS CoV and Hendra virus. HIV-1 uses a strategy to minimize or eliminate strong binding of germline antibodies to its Env; in contrast, SARS CoV and Hendra virus, and perhaps other viruses causing acute infections, can bind germline antibody or minimally somatically mutated antibodies with relatively high affinity which could be one of the reasons for the success of sG and RBD as vaccine immunogens.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22226962</PMID>
<DateCompleted><Year>2012</Year>
<Month>04</Month>
<Day>06</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>07</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1090-2104</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>417</Volume>
<Issue>4</Issue>
<PubDate><Year>2012</Year>
<Month>Jan</Month>
<Day>27</Day>
</PubDate>
</JournalIssue>
<Title>Biochemical and biophysical research communications</Title>
<ISOAbbreviation>Biochem. Biophys. Res. Commun.</ISOAbbreviation>
</Journal>
<ArticleTitle>Characterization of germline antibody libraries from human umbilical cord blood and selection of monoclonal antibodies to viral envelope glycoproteins: Implications for mechanisms of immune evasion and design of vaccine immunogens.</ArticleTitle>
<Pagination><MedlinePgn>1164-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbrc.2011.12.089</ELocationID>
<Abstract><AbstractText>We have previously observed that all known HIV-1 broadly neutralizing antibodies (bnAbs) are highly divergent from germline antibodies in contrast to bnAbs against Hendra virus, Nipah virus and SARS coronavirus (SARS CoV). We have hypothesized that because the germline antibodies are so different from the mature HIV-1-specific bnAbs they may not bind the epitopes of the mature antibodies and provided the first evidence to support this hypothesis by using individual putative germline-like predecessor antibodies. To further validate the hypothesis and understand initial immune responses to different viruses, two phage-displayed human cord blood-derived IgM libraries were constructed which contained mostly germline antibodies or antibodies with very low level of somatic hypermutations. They were panned against different HIV-1 envelope glycoproteins (Envs), SARS CoV protein receptor-binding domain (RBD), and soluble Hendra virus G protein (sG). Despite a high sequence and combinatorial diversity observed in the cord blood-derived IgM antibody repertoire, no enrichment for binders of Envs was observed in contrast to considerable specific enrichments produced with panning against RBD and sG; one of the selected monoclonal antibodies (against the RBD) was of high (nM) affinity with only few somatic mutations. These results further support and expand our initial hypothesis for fundamental differences in immune responses leading to elicitation of bnAbs against HIV-1 compared to SARS CoV and Hendra virus. HIV-1 uses a strategy to minimize or eliminate strong binding of germline antibodies to its Env; in contrast, SARS CoV and Hendra virus, and perhaps other viruses causing acute infections, can bind germline antibody or minimally somatically mutated antibodies with relatively high affinity which could be one of the reasons for the success of sG and RBD as vaccine immunogens.</AbstractText>
<CopyrightInformation>Published by Elsevier Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName>
<ForeName>Weizao</ForeName>
<Initials>W</Initials>
<AffiliationInfo><Affiliation>Protein Interactions Group, Center for Cancer Research Nanobiology Program, National Cancer Institute-Frederick, National Institutes of Health, Frederick, MD 21702, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Streaker</LastName>
<ForeName>Emily D</ForeName>
<Initials>ED</Initials>
</Author>
<Author ValidYN="Y"><LastName>Russ</LastName>
<ForeName>Daniel E</ForeName>
<Initials>DE</Initials>
</Author>
<Author ValidYN="Y"><LastName>Feng</LastName>
<ForeName>Yang</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y"><LastName>Prabakaran</LastName>
<ForeName>Ponraj</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y"><LastName>Dimitrov</LastName>
<ForeName>Dimiter S</ForeName>
<Initials>DS</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>N01CO12400</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>ZIA BC011155-01</GrantID>
<Agency>Intramural NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>N01-CO-12400</GrantID>
<Acronym>CO</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2011</Year>
<Month>12</Month>
<Day>27</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Biochem Biophys Res Commun</MedlineTA>
<NlmUniqueID>0372516</NlmUniqueID>
<ISSNLinking>0006-291X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006023">Glycoproteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019151">Peptide Library</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D056704" MajorTopicYN="Y">Adaptive Immunity</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000302" MajorTopicYN="Y">isolation & purification</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005312" MajorTopicYN="N">Fetal Blood</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006023" MajorTopicYN="N">Glycoproteins</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015497" MajorTopicYN="N">HIV-1</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045404" MajorTopicYN="N">Hendra Virus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019151" MajorTopicYN="N">Peptide Library</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year>
<Month>12</Month>
<Day>02</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2011</Year>
<Month>12</Month>
<Day>19</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2012</Year>
<Month>1</Month>
<Day>10</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2012</Year>
<Month>1</Month>
<Day>10</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2012</Year>
<Month>4</Month>
<Day>7</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">22226962</ArticleId>
<ArticleId IdType="pii">S0006-291X(11)02298-4</ArticleId>
<ArticleId IdType="doi">10.1016/j.bbrc.2011.12.089</ArticleId>
<ArticleId IdType="pmc">PMC3268823</ArticleId>
<ArticleId IdType="mid">NIHMS346637</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>MAbs. 2010 May-Jun;2(3):347-56</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20400863</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Methods Mol Biol. 2009;525:81-99, xiii</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19252835</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Immunol. 2004 Jun 1;172(11):6790-802</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15153497</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2006 Jan;80(2):891-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16378991</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2003 Dec 26;312(4):1159-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14651994</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2000 Dec;74(24):11427-36</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11090138</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Viruses. 2010 Feb;2(2):547-565</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21755021</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Science. 2005 Nov 11;310(5750):1025-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16284180</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Clin Exp Immunol. 1997 May;108(2):366-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9158112</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nucleic Acids Res. 1997 Jan 1;25(1):206-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9016537</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Science. 2011 Sep 16;333(6049):1589-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21921189</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virology. 2006 Sep 30;353(2):268-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17039602</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Bioinformatics. 2007 Nov 1;23(21):2947-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17846036</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2005 Jun;79(11):6690-702</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15890907</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Immunity. 1996 Dec;5(6):639-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8986722</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2009 Dec 18;390(3):404-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19748484</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Mol Biol. 2008 Oct 10;382(3):779-89</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18687338</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 2007 Feb 15;445(7129):732-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17301785</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Methods Mol Biol. 2009;525:129-42, xv</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19252833</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Viruses. 2009 Dec;1(3):802-17</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21994570</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Curr Top Microbiol Immunol. 1996;210:167-79</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8565555</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12123-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17620608</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001420 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001420 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:22226962 |texte= Characterization of germline antibody libraries from human umbilical cord blood and selection of monoclonal antibodies to viral envelope glycoproteins: Implications for mechanisms of immune evasion and design of vaccine immunogens. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:22226962" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |